Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity

被引:37
作者
Sacco, G
Giampietro, R
Salvatorelli, E
Menna, P
Bertani, N
Graiani, G
Animati, F
Goso, C
Maggi, CA
Manzini, S
Minotti, G
机构
[1] Univ G DAnnunzio, Dept Drug Sci, I-66013 Chieti, Italy
[2] Menarini Ric SpA, I-00040 Rome, Italy
[3] Univ Parma, Sch Med, Dept Anat Pathol, I-43100 Parma, Italy
关键词
doxorubicin; epirubicin; MEN; 10755; secondary alcohol metabolites; cardiotoxicity;
D O I
10.1038/sj.bjp.0705270
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 The anticancer anthracycline doxorubicin (DOX) causes cardiomyopathy upon chronic administration. There is controversy about whether DOX acts directly or after conversion to its secondary alcohol metabolite DOXol. Here, the role of secondary alcohol metabolites was evaluated by treating rats with cumulative doses of DOX or analogues - like epirubicin (EPI) and the novel disaccharide anthracycline MEN 10755 - which were previously shown to form less alcohol metabolites than DOX when assessed in vitro. 2 DOX induced electrocardiographic and haemodynamic alterations, like elongation of QalphaT or SalphaT intervals and suppression of isoprenaline-induced dP/dt increases, which developed in a time-dependent manner and were accompanied by cardiomegaly, histologic lesions and mortality. EPI caused less progressive or severe effects, whereas MEN 10755 caused essentially no effect. 3 DOX and EPI exhibited comparable levels of cardiac uptake, but EPI formed similar to60% lower amounts of its alcohol metabolite EPIol at 4 and 13 weeks after treatment suspension (P<0.001 vs DOX). MEN 10755 exhibited the lowest levels of cardiac uptake; hence, it converted to its alcohol metabolite MEN 10755ol similar to 40% less efficiently than did EPI to EPIol at either 4 or 13 weeks. Cardiotoxicity did not correlate with myocardial levels of DOX or EPI or MEN 10755, but correlated with those of DOXol or EPIol or MEN 10755ol (P = 0.008, 0.029 and 0.017, respectively). 4 DOX and EPI inactivated cytoplasmic aconitase, an enzyme containing an Fe - S cluster liable to disassembly induced by anthracycline secondary alcohol metabolites. DOX caused greater inactivation of aconitase than EPI, a finding consistent with the higher formation of DOXol vs EPIol. MEN 10755 did not inactivate aconitase, which was because of both reduced formation and impaired reactivity of MEN 10755ol toward the Fe - S cluster. Aconitase inactivation correlated (P<0.01) with the different levels of cardiotoxicity induced by DOX or EPI or MEN 10755. 5 These results show that (i) secondary alcohol metabolites are important determinants of anthracycline-induced cardiotoxicity, and (ii) MEN 10755 is less cardiotoxic than DOX or EPI, a behaviour attributable to impaired formation and reactivity of its alcohol metabolite.
引用
收藏
页码:641 / 651
页数:11
相关论文
共 28 条
[1]   Doxorubicin disaccharide analogue: Apoptosis-related improvement of efficacy in vivo [J].
Arcamone, F ;
Animati, F ;
Berettoni, M ;
Bigioni, M ;
Capranico, G ;
Casazza, AM ;
Caserini, C ;
Cipollone, A ;
DeCesare, M ;
Franciotti, M ;
Lombardi, P ;
Madami, A ;
Manzini, S ;
Monteagudo, E ;
Polizzi, D ;
Pratesi, G ;
Righetti, SC ;
Salvatore, C ;
Supino, R ;
Zunino, F .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (16) :1217-1223
[2]   Development of daunorubicin resistance in tumour cells by induction of carbonyl reduction [J].
Ax, W ;
Soldan, M ;
Koch, L ;
Maser, E .
BIOCHEMICAL PHARMACOLOGY, 2000, 59 (03) :293-300
[3]  
BERTAZZOLI C, 1979, CANCER TREAT REP, V63, P1877
[4]   Comparison of doxorubicin- and MEN 10755-induced long-term progressive cardiotoxicity in the rat [J].
Cirillo, R ;
Sacco, G ;
Venturella, S ;
Brightwell, J ;
Giachetti, A ;
Manzini, S .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2000, 35 (01) :100-108
[5]   MEASUREMENT OF THE S-ALPHA-T SEGMENT AS THE MOST RELIABLE ELECTROCARDIOGRAM PARAMETER FOR THE ASSESSMENT OF ADRIAMYCIN-INDUCED CARDIOTOXICITY IN THE RAT [J].
DANESI, R ;
DELTACCA, M ;
SOLDANI, G .
JOURNAL OF PHARMACOLOGICAL METHODS, 1986, 16 (03) :251-259
[6]   Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs [J].
Danesi, R ;
Fogli, S ;
Gennari, A ;
Conte, P ;
Del Tacca, M .
CLINICAL PHARMACOKINETICS, 2002, 41 (06) :431-444
[7]  
Forrest GL, 2000, CANCER RES, V60, P5158
[8]  
FORREST GL, 1991, MOL PHARMACOL, V40, P502
[9]  
GERVASI PG, 1986, ANTICANCER RES, V6, P1231
[10]  
GONZALEZ B, 1995, CANCER RES, V55, P4646